跳至主要内容
临床试验/NCT01050725
NCT01050725暂停不适用

Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study

Benaroya Research Institute1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2009年11月最近更新:
适应症

试验速览

阶段
不适用
状态
暂停
入组人数
100
试验地点
1

研究概览

简要总结

The purpose of this study is to determine whether specific assays of DNA damage repair proteins can be used in patients undergoing radiation therapy. The ultimate goal of this research is to develop clinically useful biomarkers from blood samples that could be used to customize radiation treatment for individuals, leading to reduced side effects and improved outcomes.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients > 18 years of age with primary lung, esophageal or rectal cancer receiving neo-adjuvant chemoradiotherapy before planned resection
  • patients with clinically localized prostate cancer receiving definitive radiation therapy with external beam treatment. brachytherapy as a boost and/or hormonal therapy are allowed.
  • patients with head and neck, lung, esophageal or cervical cancer who will receive definitive radiotherapy

排除标准

  • prior history of chemotherapy given within 6 months before enrollment.
  • prior radiotherapy or radionuclide treatment and/or brachytherapy within 6 months prior to enrollment.
  • unwillingness to comply with tests, protocol, or informed consent.
  • concurrent enrollment on any protocol that would require non-compliance with treatment procedures.
  • chemotherapy required within 2 hours following first dose of XRT.
  • PET scan done within 48 hours of first blood draw.
  • nuclear medicine exposure within 4 days prior to first draw.

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验